334 CAR T engagers encoding immune checkpoint inhibitors and immune-relevant cytokines stimulate CAR T cell activity against hematologic and solid tumors
Main Authors: | Paul Rennert, Lihe Su, Lan Wu, Roy Lobb, Christine Ambrose |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
by: Lihe Su, et al.
Published: (2022-12-01) -
A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2<sup>+</sup> Solid Cancer
by: Andreas A. Hombach, et al.
Published: (2023-01-01) -
Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
by: Negar Hosseinkhani, et al.
Published: (2020-11-01) -
Immune Escape in Glioblastoma: Mechanisms of Action and Implications for Immune Checkpoint Inhibitors and CAR T-Cell Therapy
by: Catherine Yu, et al.
Published: (2023-12-01) -
Immune Checkpoint Proteins, Metabolism and Adhesion Molecules: Overlooked Determinants of CAR T-Cell Migration?
by: Luca Simula, et al.
Published: (2022-06-01)